EuBiologics Co., Ltd. (KOSDAQ:206650)
South Korea · Delayed Price · Currency is KRW 14,130
+310 (2.24%)
Sep 19, 2025, 3:30 PM KST
EuBiologics Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Other Revenue | - | -0 | - | - | 0 |
| 96,035 | 69,366 | 55,467 | 39,385 | 28,490 | |
Revenue Growth (YoY) | 38.45% | 25.06% | 40.83% | 38.24% | - |
Cost of Revenue | - | 35,405 | 31,918 | 24,167 | 21,590 |
Gross Profit | 96,035 | 33,961 | 23,549 | 15,218 | 6,899 |
Selling, General & Admin | - | 7,456 | 10,499 | 5,808 | 3,624 |
Research & Development | - | 17,882 | 15,777 | 16,178 | 8,504 |
Other Operating Expenses | 61,714 | 108.88 | 223.54 | 99.44 | 80.68 |
Operating Expenses | 61,714 | 26,262 | 27,317 | 22,448 | 12,862 |
Operating Income | 34,321 | 7,699 | -3,769 | -7,230 | -5,962 |
Interest Expense | - | -488.05 | -254.92 | -588.81 | -1,967 |
Interest & Investment Income | - | 164.68 | 230.76 | 356.52 | 106.69 |
Earnings From Equity Investments | - | -512.58 | -321.04 | -124.61 | -0.15 |
Currency Exchange Gain (Loss) | - | 153.98 | -56.99 | 40.34 | -399.22 |
Other Non Operating Income (Expenses) | -10,537 | -1,191 | -657.25 | -22,818 | -55,229 |
EBT Excluding Unusual Items | 23,784 | 5,826 | -4,828 | -30,364 | -63,451 |
Gain (Loss) on Sale of Investments | - | -200.32 | 2,142 | 253.29 | -180.6 |
Gain (Loss) on Sale of Assets | - | 1,666 | 193.28 | -0.88 | -5.24 |
Asset Writedown | - | -21,906 | -845.09 | -708.04 | - |
Other Unusual Items | - | - | - | - | 3,041 |
Pretax Income | 23,784 | -14,615 | -3,338 | -30,820 | -60,595 |
Income Tax Expense | -1,082 | 745.04 | 99.24 | -2,795 | -460.79 |
Earnings From Continuing Operations | 24,866 | -15,360 | -3,437 | -28,025 | -60,134 |
Minority Interest in Earnings | - | 1,481 | 2,339 | 450.68 | - |
Net Income | 24,866 | -13,879 | -1,099 | -27,574 | -60,134 |
Net Income to Common | 24,866 | -13,879 | -1,099 | -27,574 | -60,134 |
Shares Outstanding (Basic) | - | 36 | 36 | 35 | 28 |
Shares Outstanding (Diluted) | - | 36 | 36 | 35 | 28 |
Shares Change (YoY) | - | 0.13% | 2.68% | 26.53% | - |
EPS (Basic) | - | -380.79 | -30.19 | -777.82 | -2146.27 |
EPS (Diluted) | - | -381.00 | -30.19 | -778.00 | -2146.27 |
Free Cash Flow | - | 19,515 | -2,626 | -14,196 | -6,371 |
Free Cash Flow Per Share | - | 535.43 | -72.15 | -400.46 | -227.38 |
Gross Margin | 100.00% | 48.96% | 42.45% | 38.64% | 24.22% |
Operating Margin | 35.74% | 11.10% | -6.79% | -18.36% | -20.93% |
Profit Margin | 25.89% | -20.01% | -1.98% | -70.01% | -211.07% |
Free Cash Flow Margin | - | 28.13% | -4.74% | -36.05% | -22.36% |
EBITDA | - | 16,867 | 4,113 | -665.51 | -13.19 |
EBITDA Margin | - | 24.32% | 7.42% | -1.69% | -0.05% |
D&A For EBITDA | 9,168 | 9,168 | 7,882 | 6,564 | 5,949 |
EBIT | 34,321 | 7,699 | -3,769 | -7,230 | -5,962 |
EBIT Margin | 35.74% | 11.10% | -6.79% | -18.36% | -20.93% |
Advertising Expenses | - | 186.94 | 237.98 | 47.13 | 35.88 |
Updated Mar 19, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.